BioSpectrum Asia | October 2025

Dive into the latest biotech and healthcare insights shaping Asia-Pacific.

Explore
CAR T-cell therapy is a highly personalised treatment that depends on a unique and complex manufacturing and delivery process to reach patients quickly and reliably. From leukapheresis to final product delivery, the process is continuous and timesensitive, posing significant operational challenges. How is the industry addressing them, and what steps are needed to build a sustainable manufacturing ecosystem? Let’s dig deeper.
CAR T-cell therapy is a highly personalised treatment that depends on a unique and complex manufacturing and delivery process to reach patients quickly and reliably. From leukapheresis to final product delivery, the process is continuous and timesensitive, posing significant operational challenges. How is the industry addressing them, and what steps are needed to build a sustainable manufacturing ecosystem? Let’s dig deeper.

This Month's Highlight

October Issue Cover

CAR T-cell therapy is a highly personalised treatment that depends on a unique and complex manufacturing and delivery process to reach patients quickly and reliably. From leukapheresis to final product delivery, the process is continuous and timesensitive, posing significant operational challenges. How is the industry addressing them, and what steps are needed to build a sustainable manufacturing ecosystem? Let’s dig deeper.

Explore the Issue Explore Featured Articles Explore Exclusive Interviews Advertise With Us

Exclusive Interviews

Heejin Roh "We focus on enabling early disease diagnosis through cutting-edge technologies" – Heejin Roh, Sebia
Jane Li “AI holds enormous promise to aid clinicians in making informed decisions” – Jane Li